Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Celiac Patients May Have a New Effective Drug Ahead

Posted Feb 17 2012 6:43am
Celiac disease  is an autoimmune reaction triggered by exposure to gluten, a protein found in wheat, barley, and rye, that causes the  immune system  to attack the small intestine, interfering with the absorption of nutrients and leading to malnutrition and a variety of other symptoms. The disease currently has only one treatment, which is non-drug: the gluten-free diet. By eliminating gluten completely from the diet, most celiac patients can heal their small intestine. There is currently no other drug on the market that can help relieve the  symptoms of celiac disease  or the intestinal damage it can cause.

   Now Alvine Pharmaceuticals, which is focused on developing biopharmaceuticals for autoimmune inflammatory diseases such as celiac disease, has reported favorable results for a trial with their drug ALV003, which was developed to lessen mucosal injury in the intestine caused by gluten exposure in well-controlled celiac patients. Researchers have been talking about it for some time, raising the hopes of the celiac community: a drug to help relieve us from the harmful effects of gluten exposure.

  Celiac patients are closer than ever to having such a drug on the market, as Alvine Pharmaceuticals has announced that their drug ALV003 has shown promise in a clinical trial by reducing gluten-triggered harm in people with celiac disease A control group study was conducted that collected data from 34 celiac patients. After both the active drug group and placebo group ingested two grams of gluten on a daily basis for six weeks, "The group with the placebo reported higher incidence of 'non-serious adverse events' (code for GI symptoms)," Triumph Dining reported. "They also had significantly more mucosal injury in their small intestines, as measured by biopsy data."

   Currently celiacs have no drug options to help alleviate their symptoms. "These results are groundbreaking," said Professor Maeki, "as they demonstrate for the first time, in a controlled clinical trial, that a drug has the potential to diminish gluten-induced injury in celiac disease patients." The drug is intended to help alleviate the gastrointestinal and other symptoms associated with cross-contamination, incorrect or misleading "gluten-free" labeling, and exposure to gluten caused by carelessness or imprudence.

Even when celiac patients take care to maintain a strict gluten-free, it's difficult to stay completely away from gluten. That's why, according to coordinating investigator of the latest ALV003, Markku Maeki, M.D., chair and professor of pediatrics at the University of Tampere and Tampere University Hospital in Finland, "New non-dietary treatment options that can either eliminate, or meaningfully reduce the gluten present in an attempted GFD are needed." ALV003 works by breaking down the gluten molecule into nontoxic parts. (Alvine Pharmaceuticals explains more specifically how the drug works on their website, AlvinePharma.com.)

   Triumph Dining states, "After Phase 3 trials, so long as results remain promising, ALV003 will enter Phase 2b trials soon; after that come Phase 3 trials and (hopefully) submission to the FDA for approval."

Should the results of ALV003 remain favorable, this will inevitably be a new turn for those in the celiac community as well as those with gluten sensitivity issues.

Miranda Jade Turbin

http://www.GlutenFreeHelp.info

Resources:

News-Medical.net: Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010 http://www.news-medical.net/news/20100505/Alvine-Pharmaceuticals-reports-data-of

Triumph Dining: Harm-reduction drug for celiacs shows promising results http://www.triumphdining.com/blog/2011/10/28/alv003-data-phase2a/

Alvine Pharmaceuticals: About Alvine http://www.alvinepharma.com/about-alvine/

MarketWatch: Alvine Pharmaceuticals Presents Additional Efficacy Data From Phase 2a Trial of ALV003 in Celiac Disease Patientshttp://www.marketwatch.com/story/alvine-pharmaceuticals-presents-additional-effi

Post a comment
Write a comment:

Related Searches